<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942747</url>
  </required_header>
  <id_info>
    <org_study_id>TemPCNSL</org_study_id>
    <secondary_id>EudraCT 2009-011277-33</secondary_id>
    <nct_id>NCT00942747</nct_id>
  </id_info>
  <brief_title>Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma</brief_title>
  <official_title>Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label trial investigating the efficacy of temsirolimus in recurrent or
      refractory primary CNS lymphoma (PCNSL) after initial chemotherapy with a high-dose
      methotrexate containing regimen. 37 patients are planned to be treated with weekly infusions
      of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a
      maximum of 12 months. The trial is designed in two stages, if less than one of the first 12
      patients responds to treatment, the trial is stopped. In addition to efficacy, safety and
      penetration of temsirolimus into the cerebrospinal fluid will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Weeks 4, 12, every 12 weeks thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression of disease</measure>
    <time_frame>Weeks 4, 12, every 12 weeks thereafter or upon clinical suspicion of disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penetration of temsirolimus into cerebrospinal fluid</measure>
    <time_frame>Weeks 1, 4 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Recurrent or Refractory Primary CNS Lymphoma</condition>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly IV temsirolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment</description>
    <arm_group_label>Temsirolimus</arm_group_label>
    <other_name>Torisel</other_name>
    <other_name>CCI-770</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary CNS lymphoma diagnosed histologically or by cerebrospinal fluid cytology;
             absence of systemic lymphoma manifestations

          -  Relapse or lymphoma progression after/during high-dose methotrexate containing
             first-line chemotherapy or alternative therapy in the case of contraindications
             against high-dose methotrexate

          -  ECOG performance score ≤ 2

          -  Age ≥18 years and ≤ 75 years

          -  Life expectancy of at least 3 months

          -  Absence of active infection

          -  Negative HIV serology

          -  Adequate renal function (GFR &gt;30ml/h)

          -  Adequate bone marrow reserve (neutrophils &gt; 1500/µl, platelets &gt; 80,000/µl)

          -  Bilirubin &lt;1.5x upper limit of normal (ULN), ALT and AST &lt;3x ULN

          -  At least 3 weeks interval from prior cytostatic treatment

          -  Negative pregnancy test

          -  Patient accessible for treatment and follow-up

          -  Patient compliance

          -  Signed informed consent

        Exclusion Criteria:

          -  Secondary CNS lymphoma

          -  Primary intraocular lymphoma

          -  Patient eligible for high-dose chemotherapy and autologous stem-cell transplantation

          -  Concurrent treatment within another clinical trial

          -  Concurrent other malignant disease

          -  Symptomatic congestive heart failure (≥NYHA II)

          -  Active or uncontrolled chronic infection

          -  Severe concomitant disease incompatible with study conduct

          -  History of cerebral bleeding

          -  Concomitant treatment with strong CYP3A4/5-inductors or -inhibitors

          -  Premenopausal women without highly effective contraception (defined as Pearl index &lt;1)

          -  Pregnant or lactating women

          -  Refusal to record and pass on pseudonymized disease and treatment related data as part
             of the treatment protocol

          -  Concurrent admission to a psychiatric institution by public order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnieszka Korfel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnieszka Korfel, MD</last_name>
    <phone>+49308445</phone>
    <phone_ext>4096</phone_ext>
    <email>agnieszka.korfel@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philipp Kiewe, MD</last_name>
    <phone>+493064499</phone>
    <phone_ext>5225</phone_ext>
    <email>philipp.kiewe@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Korfel, MD</last_name>
      <phone>+49308445</phone>
      <phone_ext>4096</phone_ext>
      <email>agnieszka.korfel@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Philipp Kiewe, MD</last_name>
      <phone>+493064499</phone>
      <phone_ext>5225</phone_ext>
      <email>philipp.kiewe@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Philipp Kiewe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnieszka Korfel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Neumann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Kreher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology, Knappschaftskrankenhaus Bochum, Bochum University</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Schlegel, MD</last_name>
      <phone>+49-2342993701</phone>
      <email>simone.middelhauve@kk-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Simone Middelhauve</last_name>
      <phone>+49-2342993701</phone>
      <email>simone.middelhauve@kk-bochum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Neurology, University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Herrlinger, MD</last_name>
      <phone>+49-222828719887</phone>
      <email>christiane.landwehr@ukb.uni-bonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Christiane Landwehr</last_name>
      <phone>+49-222828719887</phone>
      <email>christiane.landwehr@ukb.uni-bonn.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hematology, Klinikum Frankfurt/Oder</name>
      <address>
        <city>Frankfurt an der Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kiel, MD</last_name>
      <phone>+4933-55484604</phone>
      <email>melanie.binsker@klinikum-ffo.de</email>
    </contact>
    <contact_backup>
      <last_name>Melanie Binsker</last_name>
      <phone>+4933-55484604</phone>
      <email>melanie.binsker@klinikum-ffo.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hematology, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerlinde Egerer, MD</last_name>
      <phone>+49-6221568029</phone>
      <email>martina.gronkowski@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Martina Gronkowski</last_name>
      <phone>+49-6221568029</phone>
      <email>martina.gronkowski@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern, University Hospital Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Dreyling, MD</last_name>
      <phone>+498970955202</phone>
      <email>carmen.carlucci@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Carlucci</last_name>
      <phone>+498970955202</phone>
      <email>carmen.carlucci@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD; North American Brain Tumor Consortium and the National Cancer Institute. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15;13(24):7401-6.</citation>
    <PMID>18094423</PMID>
  </reference>
  <reference>
    <citation>Smith SM, Pro B, Cisneros A, Smith S, Stiff P, Lester E, Modi S, Dancey JE, Vokes EE, van Besien E. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol 2008:26 (May 20 suppl; abstr 8514).</citation>
  </reference>
  <reference>
    <citation>Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Aug 10;27(23):3822-9. doi: 10.1200/JCO.2008.20.7977. Epub 2009 Jul 6.</citation>
    <PMID>19581539</PMID>
  </reference>
  <reference>
    <citation>Ansell SM, Inwards DJ, Rowland KM Jr, Flynn PJ, Morton RF, Moore DF Jr, Kaufmann SH, Ghobrial I, Kurtin PJ, Maurer M, Allmer C, Witzig TE. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008 Aug 1;113(3):508-14. doi: 10.1002/cncr.23580.</citation>
    <PMID>18543327</PMID>
  </reference>
  <reference>
    <citation>Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005 Aug 10;23(23):5347-56. Epub 2005 Jun 27.</citation>
    <PMID>15983389</PMID>
  </reference>
  <reference>
    <citation>Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev. 2007 Feb;33(1):78-84. Epub 2006 Dec 11. Review.</citation>
    <PMID>17161912</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2009</study_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>PD Dr. Agnieszka Korfel</investigator_full_name>
    <investigator_title>PD Dr. Agnieszka Korfel</investigator_title>
  </responsible_party>
  <keyword>temsirolimus, primary CNS lymphoma, PCNSL, salvage treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

